NEXGEL Unveils a Groundbreaking Spin-Off
NEXGEL shareholders are poised for an exciting new chapter as the company announces a strategic spin-off of its drug delivery program into NexGelRx. This venture promises to capture up to $8 million in capital investment, allowing NEXGEL to expand its innovative healthcare offerings while maintaining a non-dilutive 19.99% equity interest in NexGelRx.
What NexGelRx Means for NEXGEL
This exciting transition enables NEXGEL to focus on its core competencies while NexGelRx concentrates on developing cutting-edge prescription drug delivery solutions. Utilizing NEXGEL’s proprietary hydrogel technology, NexGelRx aims to transform how medications are administered, providing significant benefits to patients and healthcare providers alike.
The Role of Hydrogel Technology
NEXGEL has advanced the science of hydrogel products for many years, specializing in ultra-gentle, high-water-content formulations. The unique properties of these hydrogels are set to enhance drug delivery systems. The spin-off allows NEXGEL to leverage this advanced technology fully, driving new therapeutic possibilities.
Leadership and Future Directions
Under the leadership of CEO Adam Levy, NEXGEL is optimistic about the potential for NexGelRx. Levy notes the significant opportunities available in the Rx market, emphasizing that this spin-off intends to create value for shareholders while establishing a focused pathway for growth in medical technologies.
Insight from Experts
Prominent figures in the pharmaceutical arena, such as Dr. Jerome Zeldis, have joined NexGelRx’s board. Dr. Zeldis, who carries with him a wealth of experience including launching ten pharmaceuticals, is excited about the innovations that can emerge from NexGelRx. He believes the electron beam generated hydrogel offers a viable platform for the development of transformative therapies, setting NexGelRx on a promising path.
NEXGEL’s Evolving Vision
NEXGEL isn’t just about immediate operations; it's about setting up for the future. By establishing NexGelRx, the company can tap into high-value opportunities in drug delivery without directly financing them. This strategic move facilitates sustained growth and value creation in the long term.
Continued Commitment to Quality
While NexGelRx charges ahead into new domains of prescription solutions, NEXGEL remains committed to its successful consumer brands, including SilverSeal, Hexagels, and Turfguard. With established manufacturing processes and an extensive track record in the healthcare and beauty sectors, NEXGEL is well-positioned to support its new venture while enhancing its existing product lines.
About NEXGEL, Inc.
NEXGEL stands as a leader in developing healthcare and beauty products, prominently featuring high-quality hydrogel formulations. For over two decades, NEXGEL has harnessed the potential of electron-beam technology, establishing itself as a frontrunner in innovation within the industry. Its strategic partnerships with leading companies enhance its capabilities, allowing for rapid advancements in product development.
Frequently Asked Questions
What is the main goal of the NexGelRx spin-off?
The main goal is to focus on developing and commercializing prescription drug delivery solutions that utilize NEXGEL’s hydrogel technology.
How will shareholders benefit from this spin-off?
Shareholders will retain a 19.99% equity stake and benefit from a potential return on investment as NexGelRx grows.
What role does the hydrogel technology play?
The hydrogel technology is central to developing new, effective drug delivery systems that can enhance patient care and outcomes.
Who leads the NexGelRx team?
The advisory board will include experienced professionals from NEXGEL, such as Dr. Jerome Zeldis, ensuring that the new venture is well-guided.
What is NEXGEL’s long-term vision?
NEXGEL aims to continue innovating in healthcare solutions while exploring new markets and opportunities through NexGelRx and its existing product lines.
